LD50, oral in mouse: 2690mg/kg L2125.
Ld50, subcutaneous in mouse: 1gm/kg L2125.
Interferes with thyroid function test L2132.
Gastrointestinal (GI) disorders, fatigue, hypersensitivity reactions, skin eruptions, hemolytic anemia, weakness, dyspnoea; local irritation (rectally); Reye's syndrome.
Potentially Fatal: Paroxysmal bronchospasm; hepatotoxicity; renal impairment/failure; thrombocytopenia, iron-deficiency anemia, occult bleeding, leukopenia; mild chronic salicylate intoxication L2132.
Salicylate poisoning is normally associated with plasma concentrations >350 mg/L (2.5 mmol/L). Most adult deaths due to salicylate poisoning occur in patients whose serum concentrations of salicylate are over 700 mg/L (5.1 mmol/L). Single doses of less than 100 mg/kg are very unlikely to lead to serious poisoning. Patients should be provided with supportive therapy or treatment for salicylate poisoning as necessary. This may include treatment like activated charcoal, urinary alkalinization and, in severe cases, hemodialysis L2139.
Choline salicylate is an anti-inflammatory pain reliever agent that is related to aspirin. It is used to decrease swelling and to treat mild-moderate pain. It is used to treat arthritis in both children and adults. This medicine can also be used for fever L2129.
Choline Salicylate is the choline salt of salicylic acid, used as an analgesic, antipyretic and antirheumatic. It relieves mild to moderate pain and reduce fever and inflammation or swelling. Choline salicylate is effective in the treatment of gout, rheumatic fever, rheumatoid arthritis and muscle injuries A245119.
This drug is also a main ingredient in teething gels to relieve pains associated with tooth growth in the infant population L2134. The UK government has regulated its use, due to toxicity in those under 16 years of age. Topical oral salicylate gels are no longer indicated for people younger than 16 years for pain associated with infant teething, orthodontic devices, cold sores, or mouth ulcers L2134.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Ammonium chloride | The serum concentration of Choline salicylate can be increased when it is combined with Ammonium chloride. |
| Ginkgo biloba | The risk or severity of bleeding can be increased when Ginkgo biloba is combined with Choline salicylate. |
| Methotrexate | The serum concentration of Methotrexate can be increased when it is combined with Choline salicylate. |
| Pralatrexate | The serum concentration of Pralatrexate can be increased when it is combined with Choline salicylate. |
| Probenecid | The therapeutic efficacy of Probenecid can be decreased when used in combination with Choline salicylate. |
| Treprostinil | The risk or severity of bleeding can be increased when Treprostinil is combined with Choline salicylate. |
| Bupropion | The excretion of Choline salicylate can be decreased when combined with Bupropion. |
| Ketoprofen | The risk or severity of bleeding and gastrointestinal bleeding can be increased when Choline salicylate is combined with Ketoprofen. |
| Dexketoprofen | The risk or severity of bleeding and gastrointestinal bleeding can be increased when Choline salicylate is combined with Dexketoprofen. |
| Dicoumarol | Choline salicylate may increase the anticoagulant activities of Dicoumarol. |
| Phenindione | Choline salicylate may increase the anticoagulant activities of Phenindione. |
| Phenprocoumon | Choline salicylate may increase the anticoagulant activities of Phenprocoumon. |
| Acenocoumarol | Choline salicylate may increase the anticoagulant activities of Acenocoumarol. |
| 4-hydroxycoumarin | Choline salicylate may increase the anticoagulant activities of 4-hydroxycoumarin. |
| Coumarin | Choline salicylate may increase the anticoagulant activities of Coumarin. |
| (R)-warfarin | Choline salicylate may increase the anticoagulant activities of (R)-warfarin. |
| Ethyl biscoumacetate | Choline salicylate may increase the anticoagulant activities of Ethyl biscoumacetate. |
| Fluindione | Choline salicylate may increase the anticoagulant activities of Fluindione. |
| Clorindione | Choline salicylate may increase the anticoagulant activities of Clorindione. |
| Diphenadione | Choline salicylate may increase the anticoagulant activities of Diphenadione. |
| Tioclomarol | Choline salicylate may increase the anticoagulant activities of Tioclomarol. |
| (S)-Warfarin | Choline salicylate may increase the anticoagulant activities of (S)-Warfarin. |
| Acetyldigitoxin | The serum concentration of Acetyldigitoxin can be decreased when it is combined with Choline salicylate. |
| Deslanoside | The serum concentration of Deslanoside can be decreased when it is combined with Choline salicylate. |
| Ouabain | The serum concentration of Ouabain can be decreased when it is combined with Choline salicylate. |
| Digitoxin | The serum concentration of Digitoxin can be decreased when it is combined with Choline salicylate. |
| Oleandrin | The serum concentration of Oleandrin can be decreased when it is combined with Choline salicylate. |
| Cymarin | The serum concentration of Cymarin can be decreased when it is combined with Choline salicylate. |
| Proscillaridin | The serum concentration of Proscillaridin can be decreased when it is combined with Choline salicylate. |
| Metildigoxin | The serum concentration of Metildigoxin can be decreased when it is combined with Choline salicylate. |
| Lanatoside C | The serum concentration of Lanatoside C can be decreased when it is combined with Choline salicylate. |
| Gitoformate | The serum concentration of Gitoformate can be decreased when it is combined with Choline salicylate. |
| Acetyldigoxin | The serum concentration of Acetyldigoxin can be decreased when it is combined with Choline salicylate. |
| Peruvoside | The serum concentration of Peruvoside can be decreased when it is combined with Choline salicylate. |
| Tioguanine | The metabolism of Tioguanine can be decreased when combined with Choline salicylate. |
| Mercaptopurine | The metabolism of Mercaptopurine can be decreased when combined with Choline salicylate. |
| Azathioprine | The metabolism of Azathioprine can be decreased when combined with Choline salicylate. |
| Lepirudin | The risk or severity of bleeding can be increased when Choline salicylate is combined with Lepirudin. |
| Bivalirudin | The risk or severity of bleeding can be increased when Choline salicylate is combined with Bivalirudin. |
| Alteplase | The risk or severity of bleeding can be increased when Choline salicylate is combined with Alteplase. |
| Urokinase | The risk or severity of bleeding can be increased when Choline salicylate is combined with Urokinase. |
| Reteplase | The risk or severity of bleeding can be increased when Choline salicylate is combined with Reteplase. |
| Anistreplase | The risk or severity of bleeding can be increased when Choline salicylate is combined with Anistreplase. |
| Tenecteplase | The risk or severity of bleeding can be increased when Choline salicylate is combined with Tenecteplase. |
| Abciximab | The risk or severity of bleeding can be increased when Choline salicylate is combined with Abciximab. |
| Drotrecogin alfa | The risk or severity of bleeding can be increased when Choline salicylate is combined with Drotrecogin alfa. |
| Streptokinase | The risk or severity of bleeding can be increased when Choline salicylate is combined with Streptokinase. |
| Argatroban | The risk or severity of bleeding can be increased when Choline salicylate is combined with Argatroban. |
| Ardeparin | The risk or severity of bleeding can be increased when Choline salicylate is combined with Ardeparin. |
| Fondaparinux | The risk or severity of bleeding can be increased when Choline salicylate is combined with Fondaparinux. |
| Pentosan polysulfate | The risk or severity of bleeding can be increased when Choline salicylate is combined with Pentosan polysulfate. |
| Dipyridamole | The risk or severity of bleeding can be increased when Choline salicylate is combined with Dipyridamole. |
| Heparin | The risk or severity of bleeding can be increased when Choline salicylate is combined with Heparin. |
| Enoxaparin | The risk or severity of bleeding can be increased when Choline salicylate is combined with Enoxaparin. |
| Epoprostenol | The risk or severity of bleeding can be increased when Choline salicylate is combined with Epoprostenol. |
| Ximelagatran | The risk or severity of bleeding can be increased when Choline salicylate is combined with Ximelagatran. |
| Desmoteplase | The risk or severity of bleeding can be increased when Choline salicylate is combined with Desmoteplase. |
| Defibrotide | The risk or severity of bleeding can be increased when Choline salicylate is combined with Defibrotide. |
| Ancrod | The risk or severity of bleeding can be increased when Choline salicylate is combined with Ancrod. |
| Beraprost | The risk or severity of bleeding can be increased when Choline salicylate is combined with Beraprost. |
| Prasugrel | The risk or severity of bleeding can be increased when Choline salicylate is combined with Prasugrel. |
| Rivaroxaban | The risk or severity of bleeding can be increased when Choline salicylate is combined with Rivaroxaban. |
| Sulodexide | The risk or severity of bleeding can be increased when Choline salicylate is combined with Sulodexide. |
| Semuloparin | The risk or severity of bleeding can be increased when Choline salicylate is combined with Semuloparin. |
| Idraparinux | The risk or severity of bleeding can be increased when Choline salicylate is combined with Idraparinux. |
| Cangrelor | The risk or severity of bleeding can be increased when Choline salicylate is combined with Cangrelor. |
| Astaxanthin | The risk or severity of bleeding can be increased when Choline salicylate is combined with Astaxanthin. |
| Apixaban | The risk or severity of bleeding can be increased when Choline salicylate is combined with Apixaban. |
| Otamixaban | The risk or severity of bleeding can be increased when Choline salicylate is combined with Otamixaban. |
| Amediplase | The risk or severity of bleeding can be increased when Choline salicylate is combined with Amediplase. |
| Dabigatran etexilate | The risk or severity of bleeding can be increased when Choline salicylate is combined with Dabigatran etexilate. |
| Danaparoid | The risk or severity of bleeding can be increased when Choline salicylate is combined with Danaparoid. |
| Dalteparin | The risk or severity of bleeding can be increased when Choline salicylate is combined with Dalteparin. |
| Tinzaparin | The risk or severity of bleeding can be increased when Choline salicylate is combined with Tinzaparin. |
| Nadroparin | The risk or severity of bleeding can be increased when Choline salicylate is combined with Nadroparin. |
| Triflusal | The risk or severity of bleeding can be increased when Choline salicylate is combined with Triflusal. |
| Ticagrelor | The risk or severity of bleeding can be increased when Choline salicylate is combined with Ticagrelor. |
| Ditazole | The risk or severity of bleeding can be increased when Choline salicylate is combined with Ditazole. |
| Vorapaxar | The risk or severity of bleeding can be increased when Choline salicylate is combined with Vorapaxar. |
| Edoxaban | The risk or severity of bleeding can be increased when Choline salicylate is combined with Edoxaban. |
| Potassium citrate | Potassium citrate may increase the excretion rate of Choline salicylate which could result in a lower serum level and potentially a reduction in efficacy. |
| Sodium citrate | The risk or severity of bleeding can be increased when Choline salicylate is combined with Sodium citrate. |
| Dextran | The risk or severity of bleeding can be increased when Choline salicylate is combined with Dextran. |
| Bemiparin | The risk or severity of bleeding can be increased when Choline salicylate is combined with Bemiparin. |
| Parnaparin | The risk or severity of bleeding can be increased when Choline salicylate is combined with Parnaparin. |
| Desirudin | The risk or severity of bleeding can be increased when Choline salicylate is combined with Desirudin. |
| Antithrombin Alfa | The risk or severity of bleeding can be increased when Choline salicylate is combined with Antithrombin Alfa. |
| Protein C | The risk or severity of bleeding can be increased when Choline salicylate is combined with Protein C. |
| Antithrombin III human | The risk or severity of bleeding can be increased when Choline salicylate is combined with Antithrombin III human. |
| Letaxaban | The risk or severity of bleeding can be increased when Choline salicylate is combined with Letaxaban. |
| Darexaban | The risk or severity of bleeding can be increased when Choline salicylate is combined with Darexaban. |
| Betrixaban | The risk or severity of bleeding can be increased when Choline salicylate is combined with Betrixaban. |
| Monteplase | The risk or severity of bleeding can be increased when Choline salicylate is combined with Monteplase. |
| Gabexate | The risk or severity of bleeding can be increased when Choline salicylate is combined with Gabexate. |
| Protein S human | The risk or severity of bleeding can be increased when Choline salicylate is combined with Protein S human. |
| Brinase | The risk or severity of bleeding can be increased when Choline salicylate is combined with Brinase. |
| Melagatran | The risk or severity of bleeding can be increased when Choline salicylate is combined with Melagatran. |
| Saruplase | The risk or severity of bleeding can be increased when Choline salicylate is combined with Saruplase. |
| Tocopherylquinone | The risk or severity of bleeding can be increased when Choline salicylate is combined with Tocopherylquinone. |
| Dabigatran | The risk or severity of bleeding can be increased when Choline salicylate is combined with Dabigatran. |